Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company developing genome-edited allogeneic cell therapies to treat hematologic malignancies and solid tumors. Its lead candidates are CB-010, CB-011, CB-012, and CB-020. It is collaborating with AbbVie Inc. to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.